Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Sionna Therapeutics (Nasdaq: SION) announced management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 2:00 p.m. ET.

Rhea-AI Summary

Sionna Therapeutics (Nasdaq: SION) announced management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 2:00 p.m. ET. A live webcast and a replay will be available on Sionna's Investors "Events" page.

The presentation focuses on the company’s clinical-stage programs targeting normalization of CFTR function for cystic fibrosis.

Argus Feb 4 session

-7.12% close to close Open Argus

Details

News Market Reaction – SION

On Feb 4, the day this news came out, SION closed 7.12% below the previous close.

Data tracked by StockTitan Argus for the Feb 4 session.

Market Context

On Feb 4, the day this news came out, the stock closed 7.1% below the previous close. A negative rea...

Analysis

On Feb 4, the day this news came out, the stock closed 7.1% below the previous close. A negative reaction despite this conference-focused update would fit a pattern where even constructive or neutral news, such as the positive Q3 2025 pipeline and cash update of $325.0M, has sometimes seen muted or negative follow-through. The current release mainly adds another investor-relations touchpoint without new trial readouts or financial changes. In that context, any sizable decline could reflect profit-taking near the $45.00 52-week high or sensitivity around prior insider sales rather than a shift in fundamentals.

Key Figures

Summit presentation time: 2:00 p.m. ET

Summit presentation time

2:00 p.m. ET

Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026

Historical Context

5 past events · Latest: Jan 05

5 events

1. Jan 05

   Conference presentation

   24h Move

   +4.2%

   Announced J.P. Morgan Healthcare Conference presentation and webcast access details.

2. Nov 24

   Investor conferences

   24h Move

   +1.6%

   Planned participation in two December 2025 healthcare investor conferences.

3. Nov 05

   Earnings and pipeline

   24h Move

   -1.6%

   Reported Q3 2025 results, strong cash of $325M, and multiple CF trial initiations.

4. Nov 04

   Investor conferences

   24h Move

   -1.2%

   Announced November 2025 investor conference fireside chats and webcast logistics.

5. Oct 24

   Clinical data update

   24h Move

   -1.0%

   Presented Phase 1 and preclinical data for SION‑719 and SION‑451 in CF.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cystic fibrosis, cftr, cystic fibrosis transmembrane conductance regulator

3 terms

cystic fibrosis medical

"revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing"

A genetic disease that causes the body to produce thick, sticky mucus that clogs airways and digestive passages, leading to ongoing lung infections, breathing difficulty, and problems absorbing nutrients. For investors, cystic fibrosis matters because treatments range from symptom management to pricey, targeted drugs that can change patient outcomes; progress in therapies, clinical trial results, regulatory approvals, and reimbursement decisions can significantly affect the commercial value of companies working in this area.

cftr medical

"normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein"

CFTR is a gene that makes a protein acting like a tiny gate in cell membranes to control the flow of salt and water; when the gate works properly it helps keep mucus thin and organs functioning. Investors care because mutations in CFTR drive serious diseases and create demand for diagnostics, drugs and long-term treatment revenue; progress or setbacks in therapies, approvals or patents directly affect company value.

cystic fibrosis transmembrane conductance regulator medical

"novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein"

A cystic fibrosis transmembrane conductance regulator (CFTR) is a protein that acts like a microscopic gate or faucet on cell surfaces, controlling the movement of salt and water into and out of cells. It matters to investors because mutations in CFTR cause cystic fibrosis and drive development of targeted drugs, tests, and therapies; breakthroughs or regulatory decisions around CFTR-targeting products can significantly affect the value and prospects of companies in biopharma and diagnostics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11^th, 2026 at 2:00 p.m. ET.

A live webcast of the presentation will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will also be available following the event.

About Sionna Therapeutics 
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.

Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact 
Adam Daley 
CG Life 
212.253.8881 
adaley@cglife.com

Investor Contact 
Juliet Labadorf 
ir@sionnatx.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Sionna Therapeutics (SION) present at the Guggenheim Biotech Summit 2026?

Sionna will present on Wednesday, February 11, 2026 at 2:00 p.m. ET. According to the company, management will deliver the presentation live at that scheduled time during the Guggenheim Emerging Outlook: Biotech Summit 2026.

How can investors watch Sionna Therapeutics (SION) presentation on February 11, 2026?

Investors can watch via a live webcast on Sionna’s Investors "Events" page. According to the company, the webcast will stream live and a replay will be posted after the event for on-demand viewing.

What topics will Sionna Therapeutics (SION) cover at the Guggenheim Biotech Summit?

The presentation will cover Sionna’s clinical-stage programs targeting CFTR normalization for cystic fibrosis. According to the company, management will discuss their approach to developing medicines that aim to normalize CFTR protein function.

Will a replay of Sionna Therapeutics (SION) Guggenheim presentation be available after February 11, 2026?

Yes, a replay will be made available on the company’s Investors "Events" page after the live event. According to the company, the replay will remain accessible following the presentation for investors and other viewers.